83 related articles for article (PubMed ID: 17624608)
1. Assessment of clinical response after two cycles of primary chemotherapy in breast cancer.
Beresford MJ; Stott D; Makris A
Breast Cancer Res Treat; 2008 May; 109(2):337-42. PubMed ID: 17624608
[TBL] [Abstract][Full Text] [Related]
2. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
[TBL] [Abstract][Full Text] [Related]
4. Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy.
Martincich L; Montemurro F; Cirillo S; Marra V; De Rosa G; Ponzone R; Aglietta M; Regge D
Radiol Med; 2003; 106(1-2):51-8. PubMed ID: 12951551
[TBL] [Abstract][Full Text] [Related]
5. The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer.
Clouth B; Chandrasekharan S; Inwang R; Smith S; Davidson N; Sauven P
Eur J Surg Oncol; 2007 Oct; 33(8):961-6. PubMed ID: 17215100
[TBL] [Abstract][Full Text] [Related]
6. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
Zhou B; Yang DQ; Xie F
Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
8. Primary systemic therapy of breast cancer.
Sachelarie I; Grossbard ML; Chadha M; Feldman S; Ghesani M; Blum RH
Oncologist; 2006 Jun; 11(6):574-89. PubMed ID: 16794237
[TBL] [Abstract][Full Text] [Related]
9. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.
Pickles MD; Lowry M; Manton DJ; Gibbs P; Turnbull LW
Breast Cancer Res Treat; 2005 May; 91(1):1-10. PubMed ID: 15868426
[TBL] [Abstract][Full Text] [Related]
10. CT findings of breast cancer with clinically complete response following neoadjuvant chemotherapy--histological correlation.
Ogawa Y; Nishioka A; Kubota K; Kariya S; Yoshida S; Maeda H; Tanaka Y; Moriki T; Tochika N
Oncol Rep; 2003; 10(5):1411-5. PubMed ID: 12883716
[TBL] [Abstract][Full Text] [Related]
11. MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy.
Yu HJ; Chen JH; Mehta RS; Nalcioglu O; Su MY
J Magn Reson Imaging; 2007 Sep; 26(3):615-23. PubMed ID: 17729334
[TBL] [Abstract][Full Text] [Related]
12. HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients.
Zhu L; Li YF; Chen WG; He JR; Peng CH; Zhu ZG; Li HW
Chin Med J (Engl); 2008 Oct; 121(20):1965-8. PubMed ID: 19080257
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of relative changes in serum total sialic acid level for response to neoadjuvant chemotherapy in patients with locally advanced breast carcinoma.
Celen O; Yildirim E; Ozen N; Sonmez C
Neoplasma; 2006; 53(4):347-51. PubMed ID: 16830065
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
15. [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].
Straver ME; van Adrichem JC; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Gilhuijs KG; Oldenburg HS; Wesseling J; Russell NS; Antonini N; Vrancken Peeters MT
Ned Tijdschr Geneeskd; 2008 Nov; 152(46):2519-25. PubMed ID: 19055260
[TBL] [Abstract][Full Text] [Related]
16. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy in breast cancer: which diagnostic procedures can be used?
Loehberg CR; Lux MP; Ackermann S; Poehls UG; Bani MR; Schulz-Wendtland R; Papadopoulos T; Schmucker M; Beckmann MW; Fasching PA
Anticancer Res; 2005; 25(3c):2519-25. PubMed ID: 16080487
[TBL] [Abstract][Full Text] [Related]
18. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
[TBL] [Abstract][Full Text] [Related]
19. 5-year results of cisplatin-epirubicin-vinorelbine (PEV) combination as primary chemotherapy in T2-3, N0-2 breast cancer patients: a multicentre phase II study.
Barni S; Visini M; Piazza E; Ionta MT; Ardizzoia A; Arnoldi E; Fava S; Pinotti G; Torretta F; Corradini G; Villa S; Nosenzo AM; Massidda B; Cazzaniga ME
Anticancer Res; 2007; 27(4C):3019-24. PubMed ID: 17695490
[TBL] [Abstract][Full Text] [Related]
20. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy.
Jeruss JS; Mittendorf EA; Tucker SL; Gonzalez-Angulo AM; Buchholz TA; Sahin AA; Cormier JN; Buzdar AU; Hortobagyi GN; Hunt KK
J Clin Oncol; 2008 Jan; 26(2):246-52. PubMed ID: 18056680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
